Clinical Practice Guideline Updated for Radiation Therapy for Rectal Cancer
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Dec. 11, 2024 -- In a clinical practice guideline issued by the American Society for Radiation Oncology and published online Nov. 25 in Practical Radiation Oncology, updated recommendations are presented for the use of radiation therapy (RT) for operable rectal cancer.
Jennifer Y. Wo, M.D., from Massachusetts General Hospital in Boston, and colleagues provide an update on three key questions related to the role of RT for patients with operable rectal cancer: neoadjuvant RT indications, neoadjuvant regimen selection, and indications for consideration of a nonoperative management (NOM) or local excision approach after definitive/preoperative chemoradiation.
According to the authors, neoadjuvant RT is strongly recommended for patients with stage II to III rectal cancer, but consideration of omission of neoadjuvant RT is conditionally recommended in favor of neoadjuvant chemotherapy with a favorable treatment response or upfront surgery among patients deemed at lower risk for locoregional recurrence. A total neoadjuvant therapy (TNT) approach is strongly recommended for patients with T3 to T4 and node-positive rectal cancer undergoing neoadjuvant RT. TNT with chemotherapy before or after long-course chemoradiation is strongly recommended among patients with a higher risk for locoregional recurrence, while there is a conditional recommendation for TNT with short-course RT followed by chemotherapy. Concurrent chemoradiation followed by consolidation chemotherapy is strongly recommended for patients with rectal cancer for whom NOM is a priority. Selection of RT dose-fractionation regimen, therapy sequence, and consideration of NOM should be ascertained by multidisciplinary consensus.
"These emerging treatment paradigms allow for more personalized and nuanced recommendations that are tailored to each individual patient’s level of risk as well as their priorities, providing the right balance between effective cancer control and preserving quality of life," Wo said in a statement.
Several authors disclosed ties to the biopharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-12-12 06:00
Read more
- U.S. Abortion Numbers Dipped Slightly in 2022
- FDA Grants Revascor (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation in Children with Congenital Heart Disease
- Older Adults With Migraine Experienced Higher Depression Risk During Pandemic
- Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm (epinephrine) Sublingual Film
- Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib
- Muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested dose
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions